Pharma-Bio Serv, Inc. · OTC:PBSV
Pharma-Bio Serv — Investor Presentation (June 2016)
18 slides from Pharma-Bio Serv's investor presentation, Jun 8, 2016
Slide 1: Corporate Presentation June 2016
PHARMA-BIOREEE RV CORPORATE PRESENTATION JUNE 2016
Slide 2: _ PHARMA BIGREE RV
_ PHARMA BIGREE RV 1. Who Are We 2. Our Strategy 3. Our Competitive Advantages
Slide 3: Forward Looking Statements
PHARMAIgS:ERV FORWARD LOOKING STATEMENTS This presentation contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performan
Slide 4: What We Do
What We Do FDA and International agencies regulatory compliance related services for * Pharmaceutical * Biotechnology * Chemical * Medical Device * Cosmetic * Food, Supplements, and Allied Products Industries PHARMA“ wor RV
Slide 5: Integrated Services Overview
— INTEGRATED SERVICES OVERVIEW
Slide 6: Key Data
KEY DATA + Company founded 23 years ago + Progressive diversification of services and geographies — Now offering a comprehensive portfolio: * Consulting Services (compliance, regulatory affairs, qrm, qualification, validation, FDA/EMA readiness) + Analytical Testing Services (chemical and microbiolo
Slide 7: Key Data
KEY DATA + No Losing Quarter Since Inception + Industry Leader In Regulatory And Compliance + Exceptional Management Team With A History Of Driving Strong Growth And Consistent Profits. * More Than 400 Professionals Around The Globe PHARMABIORE RV,
Slide 8: Clients include
Clients include: * 8 of the Top 10 Global Bio-Pharma Companies * 7 of the Top 10 Global Medical Technology Companies o Recognized for 10 consecutive years as one of the top Validation & Compliance Service companies in Puerto Rico by Caribbean Business. o Officesin the United States, Puerto Rico, Ire
Slide 9: Revenues - All Divisions
REVENUES - ALL DIVISIONS 38000,000 36000000}/ No losing quarter since inception due to: 34,000,000. + aia pI * Operational Flexibility $2,000,00: + No Debt + Smart Investment 27585039 23,384.86) 19,933,182 16204851 15,196,393, 14,184,445 11,479,083
Slide 10: Profile
PROFILE Stock Symbol: PBSV Exchange: OTC.QB Recent Price: $0.89 (06.02.16) 52-Week Range: $0.65 to $1.20 Shares Outst: 23M (3.1.16 Market Cap: $20.5M (0502.16) 2015 Revenue: $23M 2015 Net Income: $1.6M Cash Reserves: $15M Fiscal yearEnd: Oct31 Headquarters: Dorado, Puerto Rico ° PHARMABICREE RV
Slide 11: Our Strategy
OUR STRATEGY Organic Development and Mergers & Acquisitions Growth, combining High Profit Services (Consulting and Training) with Medium Profit, Sustainable Commodities (Testing and Calibration) PHARMABICR EE RV ou
Slide 12: Our Organic Strategy
Our Organic Strategy More Markets and Regions * Brazil's Market data!: + Population 208 Millions * Pharmaceutical local production $20 Billions + GDP $2.3 Trilllons— Unstable and slowly decreasing Economy (GDP growth rate -1.5%) * More than 600 local and international companies — 80% are locals, for
Slide 13: Our Organic Strategy
—=— Our Organic Strategy More Markets and Regions More Services Seurvzatass if METROLOGIX
Slide 14: Our Organic Strategy
—=— Our Organic Strategy More Markets and Regions More Services Same markets and services, more Industries Food Industry Energy Automotive Aerospace PHARMA: wor RV
Slide 15: Our M&A Strategy
Our M&A Strategy Retained T. R. Winston & Company for M & A Advisory. Team members include: + Michael Meyers, M.P.H., Managing Director and Head Of Investment Banking + Scott Gottlieb M.D., formerly FDA Deputy Commissioner and a Resident Fellow at the American Enterprise Institute, among other T.R.
Slide 16: Our Competitive Advantages
—— Our Competitive Advantages * Expansive Geographical Footprint * Dual Culture * Knowledge Of The Industry * Flexibility * Portfolio Of Services Covers The Full Product Life-cycle * Past Strong And Constant Performance * Strategy Potential * Experienced People PHARMA BIO ERV
Slide 17: Esteemed Board of Directors
B ~ Fs z ESTEEMED BOARD OF DIRECTORS Elizabeth Plaza - Chairman of the Board since 2006, Founder Kirk Michel - Director since 2006 Dov Perlysky - Director since 2004 Howard Spindel - Director since 2006 Irving Wiesen - Director since 2006
Slide 18: Investor Relations
Investor Relations Scott Gordon, President CorProminence 377 Oak Street Concourse 2 Garden City, NY 11530 Office: + 1.631.703.4900 scottg@corprominence.com PHARMA BIO3SERV